Aytu BioPharma Balance Sheet Health
Financial Health criteria checks 4/6
Aytu BioPharma has a total shareholder equity of $29.8M and total debt of $16.6M, which brings its debt-to-equity ratio to 55.5%. Its total assets and total liabilities are $115.8M and $86.0M respectively.
Key information
55.5%
Debt to equity ratio
US$16.56m
Debt
| Interest coverage ratio | n/a |
| Cash | US$20.11m |
| Equity | US$29.83m |
| Total liabilities | US$86.01m |
| Total assets | US$115.83m |
Recent financial health updates
Recent updates
Financial Position Analysis
Short Term Liabilities: 0A8M's short term assets ($60.7M) do not cover its short term liabilities ($61.3M).
Long Term Liabilities: 0A8M's short term assets ($60.7M) exceed its long term liabilities ($24.8M).
Debt to Equity History and Analysis
Debt Level: 0A8M has more cash than its total debt.
Reducing Debt: 0A8M's debt to equity ratio has increased from 0% to 55.5% over the past 5 years.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: 0A8M has sufficient cash runway for more than 3 years based on its current free cash flow.
Forecast Cash Runway: 0A8M has sufficient cash runway for 1.9 years if free cash flow continues to grow at historical rates of 15.5% each year.